| Literature DB >> 29579961 |
M Figueiredo-González1, P Reboredo-Rodríguez2, C González-Barreiro3, J Simal-Gándara4, P Valentão5, A Carrasco-Pancorbo6, P B Andrade7, B Cancho-Grande8.
Abstract
In this work, phenol-rich extracts from 'Cornicabra' and 'Picual' virgin-olive oils (EVOOs) were examined, for the first time, to establish their capacity to inhibit key enzymes involved in Alzheimer's disease (AD) (acetylcholinesterase (AChE), butyrylcholinesterase (BuChE) and 5-lipoxygenase (LOX)), major depressive disorder (MDD) and Parkinson's disease (PD) (monoamine oxidases: hMAO-A and hMAO-B respectively), and diabetes mellitus (DM) (α-glucosidase and α-amylase). 'Cornicabra' displayed the best inhibitory activity against all enzymes, when compared to 'Picual': BuChE (IC50 = 156 ± 4 and 308 ± 33 mg mL-1), LOX (IC50 = 26 ± 0.5 and 37 ± 3 mg mL-1), hMAO-A (IC50 = 20 ± 2 and 37 ± 0.2 mg mL-1), hMAO-B (IC50 = 131 ± 7 and 215 ± 13 mg mL-1) and α-glucosidase (IC50 = 154 ± 17 and 251 ± 31 mg mL-1), respectively. The behaviour observed can be associated with the higher content of secoiridoids, lignans and phenolic acids in 'Cornicabra' EVOO.Entities:
Keywords: Cornicabra cv.; Diabetes mellitus; Extra-virgin olive oil; Neuroprotection; Phenols; Picual cv.
Mesh:
Substances:
Year: 2018 PMID: 29579961 DOI: 10.1016/j.foodres.2018.01.026
Source DB: PubMed Journal: Food Res Int ISSN: 0963-9969 Impact factor: 6.475